Triamcinolone suppresses retinal vascular pathology via a potent interruption of proinflammatory signal-regulated activation of VEGF during a relative hypoxia

Neurobiology of Disease

Volumn 26, Issue 3, 2007, Pages 569-576

  Kim, Y H ^a   Chung, I Y ^b   Choi, M Y ^a   Kim, Y S ^a   Lee, J H ^a   Park, C H ^a   Kang, S S ^a   Roh, G S ^a   Choi, W S ^a   Yoo, J M ^b   Cho, G J ^a  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Institute of Health Sciences   (South Korea)

Author keywords

Hypoxia; Hypoxia response proinflammatory genes; OIR; Retina; TA; VEGF

Indexed keywords

EVANS BLUE; FLUORESCEIN ISOTHIOCYANATE; TRIAMCINOLONE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYPOXIA; IMMUNOBLOTTING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RETINA; RETINA BLOOD VESSEL OCCLUSION; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS; BODY WEIGHT; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; FEMALE; GENE EXPRESSION REGULATION; HYPEROXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION MEDIATORS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; RETINAL ARTERY; RETINAL DISEASES; SIGNAL TRANSDUCTION; TRIAMCINOLONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34248595599     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.02.002     Document Type: Article

References (51)

1. Abeyama K., Eng W., Jester J.V., Vink A.A., Edelbaum D., Cockerell C.J., Bergstresser P.R., and Takashima A. A role for NF-kappaB-dependent gene transactivation in sunburn. J. Clin. Invest. 105 (2000) 1751-1759
2. Al-Shabrawey M., Bartoli M., El-Remessy A.B., Platt D.H., Matragoon S., Behzadian M.A., Caldwell R.W., and Caldwell R.B. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am. J. Pathol. 167 (2005) 599-607
3. Boddy J.L., Fox S.B., Han C., Campo L., Turley H., Kanga S., Malone P.R., and Harris A.L. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin. Cancer Res. 11 (2005) 7658-7663
4. Brafman A., Mett I., Shafir M., Gottlieb H., Damari G., Gozlan-Kelner S., Vishnevskia-Dai V., Skaliter R., Einat P., Faerman A., Feinstein E., and Shoshani T. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest. Ophthalmol. Visual Sci. 45 (2004) 3796-3805
5. Browning J., Wylie C.K., and Gole G. Quantification of oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Visual Sci. 38 (1997) 1168-1174
6. Chou E., Suzuma I., Way K.J., Opland D., Clermont A.C., Naruse K., Suzuma K., Bowling N.L., Vlahos C.J., Aiello L.P., and King G.L. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105 (2002) 373-379
7. Comer G.M., and Ciulla T.A. Pharmacotherapy for diabetic retinopathy. Curr. Opin. Ophthalmol. 15 (2004) 508-518
8. De Bosscher K., Vanden Berghe W., Beck I.M., Van Molle W., Hennuyer N., Hapgood J., Libert C., Staels B., Louw A., and Haegeman G. A fully dissociated compound of plant origin for inflammatory gene repression. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15827-15832
9. Donadelli R., Zanchi C., Morigi M., Buelli S., Batani C., Tomasoni S., Corna D., Rottoli D., Benigni A., Abbate M., Remuzzi G., and Zoja C. Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways. J. Am. Soc. Nephrol. 14 (2003) 2436-2446
10. Gardiner T.A., Gibson D.S., de Gooyer T.E., de la Cruz V.F., McDonald D.M., and Stitt A.W. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am. J. Pathol. 166 (2005) 637-644
11. Garside H., Stevens A., Farrow S., Normand C., Houle B., Berry A., Maschera B., and Ray D. Glucocorticoid ligands specify different interactions with NF-kappaB by allosteric effects on the glucocorticoid receptor DNA binding domain. J. Biol. Chem. 279 (2004) 50050-50059
12. Haddad J.J. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell. Signal. 14 (2002) 879-897
13. Haddad J.J., and Harb H.L. l-gamma-Glutamyl-l-cysteinyl-glycine (glutathione; GSH) and GSH-related enzymes in the regulation of pro- and anti-inflammatory cytokines: a signaling transcriptional scenario for redox(y) immunologic sensor(s)?. Mol. Immunol. 42 (2005) 987-1014
14. Hammes H.P., Lin J., Renner O., Shani M., Lundqvist A., Betsholtz C., Brownlee M., and Deutsch U. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51 (2002) 3107-3112
15. Hellwig-Burgel T., Rutkowski K., Metzen E., Fandrey J., and Jelkmann W. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 94 (1999) 1561-1567
16. Hoffmann J., Feng Y., vom Hagen F., Hillenbrand A., Lin J., Erber R., Vajkoczy P., Gourzoulidou E., Waldmann H., Giannis A., Wolburg H., Shani M., Jaeger V., Weich H.A., Preissner K.T., Hoffmann S., Deutsch U., and Hammes H.P. Endothelial survival factors and spatial completion, but not pericyte coverage of retinal capillaries determine vessel plasticity. FASEB J. 19 (2005) 2035-2036
17. Hosokawa Y., Hosokawa I., Ozaki K., Nakae H., and Matsuo T. Increase of CCL20 expression by human gingival fibroblasts upon stimulation with cytokines and bacterial endotoxin. Clin. Exp. Immunol. 142 (2005) 285-291
18. Hu L., Shi Y., Hsu J.H., Gera J., Van Ness B., and Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101 (2003) 3126-3135
19. Ishida S., Usui T., Yamashiro K., Kaji Y., Amano S., Ogura Y., Hida T., Oguchi Y., Ambati J., Miller J.W., Gragoudas E.S., Ng Y.S., D'Amore P.A., Shima D.T., and Adamis A.P. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med. 198 (2003) 483-489
20. Ishida Y., Kondo T., Kimura A., Matsushima K., and Mukaida N. Absence of IL-1 receptor antagonist impaired wound healing along with aberrant NF-kappaB activation and a reciprocal suppression of TGF-beta signal pathway. J. Immunol. 176 (2006) 5598-5606
21. Itakura H., Akiyama H., Hagimura N., Doi H., Tanaka T., Kishi S., and Kurabayashi M. Triamcinolone acetonide suppresses interleukin-1 beta-mediated increase in vascular endothelial growth factor expression in cultured rat Muller cells. Graefe's Arch. Clin. Exp. Ophthalmol. 244 (2006) 226-231
22. Jeong H.J., Chung H.S., Lee B.R., Kim S.J., Yoo S.J., Hong S.H., and Kim H.M. Expression of proinflammatory cytokines via HIF-1alpha and NF-kappaB activation on desferrioxamine-stimulated HMC-1 cells. Biochem. Biophys. Res. Commun. 306 (2003) 805-811
23. Jonas J.B., Kreissig I., Kamppeter B., and Degenring R.F. [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases]. Ophthalmologe 101 (2004) 113-120
24. Jonas J.B., Kreissig I., and Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog. Retinal Eye Res. 24 (2005) 587-611
25. Kijlstra A., La Heij E., and Hendrikse F. Immunological factors in the pathogenesis and treatment of age-related macular degeneration. Ocul. Immunol. Inflamm. 13 (2005) 3-11
26. Kim Y.H., Kim Y.S., Kang S.S., Noh H.S., Kim H.J., Cho G.J., and Choi W.S. Expression of 14-3-3 zeta and interaction with protein kinase C in the rat retina in early diabetes. Diabetologia 48 (2005) 1411-1415
27. Kim Y.H., Kim Y.S., Noh H.S., Kang S.S., Cheon E.W., Park S.K., Lee B.J., Choi W.S., and Cho G.J. Changes in rhodopsin kinase and transducin in the rat retina in early-stage diabetes. Exp. Eye Res. 80 (2005) 753-760
28. Kwak N., Okamoto N., Wood J.M., and Campochiaro P.A. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Visual Sci. 41 (2000) 3158-3164
29. Lamagna C., Hodivala-Dilke K.M., Imhof B.A., and Aurrand-Lions M. Antibody against functional adhesion molecule-C inhibits angiogenesis and tumor growth. Cancer Res. 65 (2005) 5703-5710
30. Lavie G., Mandel M., Hazan S., Barliya T., Blank M., Grunbaum A., Meruelo D., and Solomon A. Anti-angiogenic activities of hypericin in vivo: potential for ophthalmologic applications. Angiogenesis 8 (2005) 35-42
31. Marti H.J., Bernaudin M., Bellail A., Schoch H., Euler M., Petit E., and Risau W. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am. J. Pathol. 156 (2000) 965-976
32. Matsuda S., Gomi F., Oshima Y., Tohyama M., and Tano Y. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest. Ophthalmol. Visual Sci. 46 (2005) 1062-1068
33. Miyamoto N., Mandai M., Takagi H., Suzuma I., Suzuma K., Koyama S., Otani A., Oh H., and Honda Y. Contrasting effect of estrogen on VEGF induction under different oxygen status and its role in murine ROP. Invest. Ophthalmol. Visual Sci. 43 (2002) 2007-2014
34. Ozdek S.C., Aydin B., Gurelik G., Bahceci U., and Hasanreisoglu B. Effects of intravitreal triamcinolone injection on macular edema and visual prognosis in central retinal vein occlusion. Int. Ophthalmol. 16 (2006) 27-34
35. Reynolds L.E., Wyder L., Lively J.C., Taverna D., Robinson S.D., Huang X., Sheppard D., Hynes R.O., and Hodivala-Dilke K.M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 8 (2002) 27-34
36. Sarlos S., Rizkalla B., Moravski C.J., Cao Z., Cooper M.E., and Wilkinson-Berka J.L. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am. J. Pathol. 163 (2003) 879-887
37. Sears J.E., and Hoppe G. Triamcinolone acetonide destabilizes VEGF mRNA in Muller cells under continuous cobalt stimulation. Invest. Ophthalmol. Visual Sci. 46 (2005) 4336-4341
38. Sharma R.K., Sodhi A., and Batra H.V. Involvement of c-Jun N-terminal kinase in rF1 mediated activation of murine peritoneal macrophages in vitro. J. Clin. Immunol. 25 (2005) 215-223
39. Simpson D.A., Murphy G.M., Bhaduri T., Gardiner T.A., Archer D.B., and Stitt A.W. Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia. Biochem. Biophys. Res. Commun. 262 (1999) 333-340
40. Spaide R.F., Sorenson J., and Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110 (2003) 1517-1525
41. Spaide R.F., Sorenson J., and Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 25 (2005) 685-690
42. Spaide R.F., Sorenson J., and Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112 (2005) 301-304
43. Taylor C.T., and Colgan S.P. Therapeutic targets for hypoxia-elicited pathways. Pharm. Res. 16 (1999) 1498-1505
44. Taylor C.T., Fueki N., Agah A., Hershberg R.M., and Colgan S.P. Critical role of cAMP response element binding protein expression in hypoxia-elicited induction of epithelial tumor necrosis factor-alpha. J. Biol. Chem. 274 (1999) 19447-19454
45. Uckermann O., Kutzera F., Wolf A., Pannicke T., Reichenbach A., Wiedemann P., Wolf S., and Bringmann A. The glucocorticoid Triamcinolone acetonide inhibits osmotic swelling of retinal glial cells via stimulation of endogenous adenosine signaling. J. Pharmacol. Exp. Ther. 315 (2005) 1036-1045
46. Vinores S.A., Xiao W.H., Aslam S., Shen J., Oshima Y., Nambu H., Liu H., Carmeliet P., and Campochiaro P.A. Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J. Cell. Physiol. 206 (2006) 749-758
47. Wilkinson-Berka J.L., Jones D., Taylor G., Jaworski K., Kelly D.J., Ludbrook S.B., Willette R.N., Kumar S., and Gilbert R.E. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest. Ophthalmol. Visual Sci. 47 (2006) 1600-1605
48. Xu Q., Qaum T., and Adamis A.P. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest. Ophthalmol. Visual Sci. 42 (2001) 789-794
49. Yang Z.F., Poon R.T., To J., Ho D.W., and Fan S.T. The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res. 64 (2004) 5496-5503
50. Yuan H.T., Li X.Z., Pitera J.E., Long D.A., and Woolf A.S. Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1 alpha. Am. J. Pathol. 163 (2003) 2289-2301
51. Zhang S.X., Wang J.J., Gao G., Shao C., Mott R., and Ma J.X. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J. 20 (2006) 323-325